Novartis, a Swiss multinational pharmaceutical corporation, announced it plans to make a $23 billion investment over five years in U.S.-based infrastructure. In a press release, the company said “all key Novartis medicines for US patients will be made in the United States.” “As a Swiss-based company with a significant presence in the U.S., these investments will enable us to fully bring our supply chain and key technology platforms into the U.S. to support our strong U.S. growth outlook,” Novartis CEO Vas Narasimhan said in a statement. pic.twitter.com/tCRMFGEWuq — The Epoch Times (@EpochTimes) April 11, 2025 “This commitment enables Novartis to expand on its current manufacturing, research and technology presence across the country with 10 facilities, including 7 brand new facilities, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional US jobs. The production capacity will cover both active pharmaceutical ingredients (API) and biologics drug substance, as well as secondary production and packaging,” Novartis stated. Over the next five years, Novartis will: Establish 1 biomedical research innovation hub in San Diego, CA, its second global R&D hub in the US Build 4 new manufacturing facilities in soon-to-be-determined states, including 3 that will make biologics drug substances, drug products, device assembly and packaging, and 1 facility that will make chemical drug substances, oral solids dosage forms and packaging Build 2 new radioligand therapy (RLT) manufacturing facilities in Florida and Texas Expand 3 RLT manufacturing facilities in Indianapolis, IN, Millburn, NJ, and Carlsbad, CA Swiss pharmaceutical giant Novartis said it would invest $23 billion in the US over the next five years to ensure all its key drugs for Americans are made in the country https://t.co/4UUYrhP2MX — Bloomberg (@business) April 10, 2025 From Novartis: With these investments, Novartis will have manufacturing capacity in the US for all its core technology platforms, including small molecules and biologics. Novartis already manufactures its most innovative, advanced therapies in the US for patients in the US and around the world. This includes cutting-edge technology platforms like gene and cell therapy and RLT manufacturing. This new investment will bring internal manufacturing of the company’s siRNA technology to the US for the first time and reflects a commitment to increase US manufacturing across its main therapeutic areas: oncology, immunology, neuroscience, and cardiovascular, renal and metabolic. With new manufacturing capacity, Novartis will be able to produce 100% of its key medicines end-to-end in the US, a significant increase from current levels. “As a Swiss-based company with a significant presence in the US, these investments will enable us to fully bring our supply chain and key technology platforms into the US to support our strong US growth outlook. These investments also reflect the pro-innovation policy and regulatory environment in the US that supports our ability to find the next medical breakthroughs for patients,” said Vas Narasimhan, CEO of Novartis. “We are prepared for shifts in the external environment and fully confident in our 2025 guidance, mid- to long-term sales growth outlook and 2027 core margin guidance of 40%+.” The investment includes a newly planned $1.1 billion research hub in San Diego, a state-of-the-art research facility that will provide world-class scientific infrastructure and drug discovery capabilities to enhance and strengthen the efforts of Novartis scientists working to reimagine the future of medicine. The new complex, expected to open between 2028 and 2029, will serve as the epicenter of the Novartis West Coast Biomedical Research presence, complementing existing hubs in Cambridge, MA, and Basel, Switzerland. In addition, the company will be expanding RLT manufacturing with new facilities in Florida and Texas. Novartis is the only organization with a dedicated commercial RLT portfolio, and has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production facilities. To support growing demand for RLTs in the US, Novartis has already expanded production capabilities in Millburn, NJ, and a state-of-the-art facility in Indianapolis, IN, and is currently building a third US RLT manufacturing facility in Carlsbad, CA. The US is a priority market for Novartis, and the company has taken numerous steps over its 200-year history to build its US infrastructure. Over the next 5 years, the total investment in Novartis US operations is expected to be nearly $50 billion, marking a clear demonstration of the company’s focus on the US. #News: We are expanding our US-based manufacturing and R&D footprint with a planned $23B investment over the next 5 years. https://t.co/jGBfesZqhb #NovartisUS pic.twitter.com/lYfaETHFuW — Novartis US (@NovartisUS) April 10, 2025 TRUMP EFFECT: Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threatshttps://t.co/2amc25Q44Y — Rapid Response 47 (@RapidResponse47) April 10, 2025 Per Reuters: The announcement comes two days after President Donald Trump said the U.S. will soon announce a “major” tariff on pharmaceutical imports, sending shares of drugmakers plunging. “We believe we can manage the tariffs – though of course they will be very painful – so while that is a factor (behind this investment), it’s not the driving factor,” Novartis Chief Executive Vas Narasimhan said in an interview, adding that it aims to produce all the drugs it sells to Americans in the U.S. rather than import them. The Basel, Switzerland-based drugmaker has previously said it hoped to become a top-five player in the U.S. pharmaceuticals market, the largest in the world, as part of a U.S.-first strategy. Over the next five years, Novartis’ total investment in U.S. operations is expected to reach nearly $50 billion, the company said. U.S. drugmakers including Eli Lilly and Johnson & Johnson announced their own U.S. manufacturing investments earlier this year, with Lilly committing to spend $27 billion on U.S. plants over five years.